The Neulasta market in the United Kingdom is projected to grow at a CAGR of 3.7%, driven by NHS support for cancer care and the adoption of biosimilar alternatives. Market drivers include government funding for oncology treatment and efforts to reduce neutropenia-related hospitalizations. However, cost-containment measures and regulatory delays in new product introductions restrain rapid expansion. Opportunities exist in expanding biosimilar access and increasing clinical adoption of Onpro kits for home use. Trends include a focus on reducing hospital visits and improving patient quality of life through subcutaneous self-administration options.
TABLE - United Kingdom Neulasta Market Size & Forecast By Drug Type 2021-2033
| Drug Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Branded | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Biosimilars | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - United Kingdom Neulasta Market Size & Forecast By Distribution Channel 2021-2033
| Distribution Channel | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Retail Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Online Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - United Kingdom Neulasta Market Size & Forecast By Route of Administration 2021-2033
| Route of Administration | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-filled Syringes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| On-body Injectors (OBI) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - United Kingdom Neulasta Market Size & Forecast By End User 2021-2033
| End User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer Treatment Centers | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Hospitals | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Homecare Settings | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis